<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590277</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-026-11F</org_study_id>
    <nct_id>NCT01590277</nct_id>
  </id_info>
  <brief_title>Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans</brief_title>
  <official_title>Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcohol is abused commonly, but there is no remedy for alcohol intoxication. This project is&#xD;
      looking at the substance iomazenil and its effect on alcohol intoxication and alcohol's&#xD;
      effects on driving an automobile.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alcohol is abused commonly, but there is no antidote for alcohol intoxication the way&#xD;
      naltrexone or naloxone is an antidote for opioids. A medication that has the potential to&#xD;
      block alcohol actions in the Central Nervous System could act as a unique medication in the&#xD;
      treatment of alcohol intoxication and alcoholism. This project is evaluating the&#xD;
      benzodiazepine partial inverse agonist, iomazenil, as an agent that could reverse alcohol's&#xD;
      effects on subjective intoxication, alcohol's effects on driving using a driving simulator&#xD;
      and on measures of electrophysiology in the laboratory in healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2012</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Automobile driving</measure>
    <time_frame>4 years</time_frame>
    <description>Driving stimulator</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Active Ethanol and Active Iomazenil</condition>
  <condition>Active Ethanol and Placebo Iomazenil</condition>
  <condition>Placebo Ethanol and Placebo Iomazenil</condition>
  <condition>Placebo Ethanol and Active Iomazenil</condition>
  <arm_group>
    <arm_group_label>ethanol and iomazenil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.&#xD;
Potential Randomizations:&#xD;
placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo ethanol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.&#xD;
Potential Randomizations:&#xD;
placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active iomazenil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.&#xD;
Potential Randomizations:&#xD;
placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo iomazenil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.&#xD;
Potential Randomizations:&#xD;
placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethanol</intervention_name>
    <description>Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.&#xD;
Potential Randomizations:&#xD;
placebo ethanol + and placebo iomazenil&#xD;
active ethanol + placebo iomazenil&#xD;
active ethanol + active iomazenil&#xD;
placebo ethanol + active iomazenil</description>
    <arm_group_label>active iomazenil</arm_group_label>
    <arm_group_label>ethanol and iomazenil</arm_group_label>
    <arm_group_label>placebo ethanol</arm_group_label>
    <arm_group_label>placebo iomazenil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iomazenil</intervention_name>
    <description>Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.&#xD;
Potential Randomizations:&#xD;
placebo ethanol + and placebo iomazenil&#xD;
active ethanol + placebo iomazenil&#xD;
active ethanol + active iomazenil&#xD;
placebo ethanol + active iomazenil</description>
    <arm_group_label>active iomazenil</arm_group_label>
    <arm_group_label>ethanol and iomazenil</arm_group_label>
    <arm_group_label>placebo ethanol</arm_group_label>
    <arm_group_label>placebo iomazenil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males&#xD;
&#xD;
          -  21-35 years old&#xD;
&#xD;
          -  Medically healthy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under the age of 21 or greater than the age 35&#xD;
&#xD;
          -  History of seizures&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak D'Souza, MD MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CERC (VISN1, West Haven, CT)</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 30, 2012</study_first_submitted>
  <study_first_submitted_qc>April 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2012</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

